Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. infantis 35624 vs L. acidophilus: B. infantis 35624 has the stronger overall evidence (5 vs 5/10); they're alternatives for improve digestion — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
B. infantis 35624 wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
1 x 10^8 CFU (100 million) daily — the dose that won the only head-to-head dose comparison; 1 x 10^10 CFU also beat placebo in a separate trial, so higher doses are not ruled out
any
Freeze-dried capsule standardized to 35624 at 1 x 10^8 CFU
1-100 billion CFU (10^9 to 10^11) per serving — the range FDA reviewed without objection for L. acidophilus DDS-1 in foods generally (GRAS Notice GRN 871); La-14 was noticed at 1 billion CFU per 250 g serving (GRN 502)
any
A product naming its strain (e.g. NCFM, DDS-1, La-14, La-5)
4 weeks
4 weeks
n/a
n/a
Weeks
Weeks
Course of antibiotics
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Am J Gastroenterol (2006) · Rct · n=362
1 x 10^8 CFU significantly superior to placebo AND to all other doses for the primary endpoint of abdominal pain
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
Gastroenterology (2005) · Rct · n=77
Beat placebo on composite score and on abdominal pain, bloating/distention and bowel-movement difficulty for most treatment weeks
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Curr Med Res Opin (2017) · Meta analysis
Single-strain 35624 had no effect on abdominal pain, bloating/distention, or bowel-habit satisfaction
Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
Nutrients (2020) · Rct
Multicentre randomised controlled trial in irritable bowel syndrome (PubMed publication types: Randomized Controlled Trial, Multicenter Study)
The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial.
Nutr J (2016) · Crossover
Randomised, double-blind, placebo-controlled crossover trial (PubMed publication types: Randomized Controlled Trial)
Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.
Lancet (2013) · Rct
Randomised, double-blind, placebo-controlled multicentre trial in inpatients aged 65 and over (PubMed publication types: Randomized Controlled Trial, Multicenter Study)
B. infantis 35624 has a higher evidence score (5/10 vs 5/10) and wins in 1 of 3 categories.
For improve digestion, B. infantis 35624 has a higher relevance score (58 vs 55).
No known interactions between B. infantis 35624 and L. acidophilus have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.